Roxithromycin Compared to Doxycycline in the Treatment of Genital Chlamydial Infection and Non-Specific Urethritis

Abstract

A single-blind randomized follow-up study was conducted to evaluate the efficacy and tolerance of roxithromycin 300 mg once a day compared to doxycycline 200 mg day 1 and 100 mg day 2–10 in the treatment of genital chlamydial infection in men and women and non-specific urethritis (NSU) in men. A total of 211 patients (200 men and 11 women) between 18 and 46 years were enrolled. The women were excluded from the efficacy analysis because of the low number, but were included in the tolerance analysis. The clinical (clearance of polymorphonuclear leucocytes in urethral smears) and bacteriological response was evaluated one and 11 days after the treatment. Of 113 included men with chlamydial infection, 105 (93%) and 96 (85%) were evaluable on respective follow-up visits and of 87 included men with NSU, 74 (85%) and 64 (74%) were evaluable one and 11 days after treatment, respectively. The bacteriological eradication rate immediately after the treatment in chlamydia positive patients was 92.7% and 100% for roxithromycin and doxycycline, respectively, and 91.8% and 100% at follow-up. The clinical cure rate of all evaluable patients was 83.1% and 80.7% for roxithromycin and doxycycline, respectively, one day after the treatment and 80.5% and 85.3% for the two drugs, respectively, 11 days after treatment. None of these observed differences was statistically significant. The diagnosis did not influence the clinical response rate with either drug. Probable and possible drug-related side-effects were more common after doxycycline than after roxithromycin, 35% and 19% respectively (P = 0.0032). The side effects were mainly mild gastro-intestinal symptoms with short duration and none of the patients receiving roxithromycin stopped the treatment. Roxithromycin, belonging to a new generation of macrolides related to erythromycin, can be given as an effective single daily dose of 300 mg for 10 days to cure genital chlamydial infection and NSU in men, and its efficacy is comparable with that of doxycycline in standard recommended dose. Roxithromycin was shown to be safe and it had fewer and milder side-effects than doxycycline.

Keywords

Chlamydial infection doxycycline non-specific urethritis roxithromycin

Get full access to this article

View all access options for this article.

References

Worm

Hoff

Kroon

Petersen

Christiansen

JJ.

Roxithromycin compared with erythromycin against genitourinary chlamydial infections. Genitourin Med 1989;65:35–38.

Ripa

Mårdh

P-A.

Cultivation of Chlamydia trachomatis in cyclohexemide-treated McCoy cells. J Clin Microbiol 1977;6:328–31.

Young

Gonzales

Sorkin

EM.

Roxithromycin. A review of its Antibacterial Activity, Pharmacokinetic properties and Clinical Efficacy. Drugs 1989;37:8–41.

Jordan

WC.

Doxycycline vs tetracycline in the treatment of men with gonorrhea. The compliance factor. Sex Transm Dis 1981;8(suppl):105–9.

van der Willigen

Tjiam

Wagenvoort

JHT

Polak-Vogelsang

Michel

Stoltz

Evaluation of roxithromycin in the treatment of non-gonococcal urethritis in males. Eur J Clin Microbiol 1986;5:612–14.

Arya

Mallinson

Andrews

Sills

Diagnosis of urethritis: Role of polymorphonuclear leucocyte counts in Gram-stained urethral smears. Sex Transm Dis 1984;1:10–17.

Worm

A-M.

Roxithromycin and erythromycin in chlamydia-negative non-gonococcal urethritis. Acta Derm Venereol (Stockh) 1990;70:269–71.